@article{dd094405bf9149cbae405f38a28b3de1,
title = "Stroke intervention: Catheter-based therapy for acute ischemic stroke",
abstract = "The majority (>80\%) of the three-quarters of a million strokes that will occur in the United States this year are ischemic in nature. The treatment of acute ischemic stroke is very similar to acute myocardial infarction, which requires timely reperfusion therapy for optimal results. The majority of patients with acute ischemic stroke do not receive any form of reperfusion therapy, unlike patients with acute myocardial infarction. Improving outcomes for acute stroke will require patient education to encourage early presentation, an aggressive expansion of qualified hospitals, and willing providers and early imaging strategies to match patients with their best options for reperfusion therapy to minimize complications.",
keywords = "angioplasty, neurovascular, stent, thrombectomy, thrombolysis",
author = "White, \{Christopher J.\} and Alex Abou-Chebl and Cates, \{Christopher U.\} and Levy, \{Elad I.\} and McMullan, \{Paul W.\} and Krishna Rocha-Singh and Weinberger, \{Jesse M.\} and Wholey, \{Mark H.\}",
note = "Funding Information: Dr. White has received research support from Boston Scientific Corporation. Dr. Abou-Chebl has served as a consultant to Arterain Medical, Inc., and a speaker for Bristol-Myers Squibb/Sanofi. Dr. Levy has received research support from Boston Scientific Corporation, Codman and Shurtleff, Inc., and Ev3/Covidien Vascular Therapies; has served as consultant to TheraSyn Sensors, Inc., Codman \& Shurtleff, Inc., Ev3/Covidien Vascular Therapies, and Abbot Vascular; has ownership stock in Intratech Medical, Ltd., and Mynx/Access Closure; and has received honoraria from Boston Scientific Corporation. Dr. Weinberger has served on a blinded Adjudication Adverse Events Committee for clinical trials for Novartis and Genentech. Dr. Wholey is the founder of Neurovascular Interventions Technology; has served as a consultant to Abbott Vascular, Medrad Inc., Boston Scientific, Covidien Inc., and Access Closure Inc.; is a shareholder in NeuroInterventions Inc., Boston Scientific, and Access Closure; and has a royalty agreement with Covidien Inc. All other authors have reported that they have no relationships to disclose. ",
year = "2011",
month = jul,
day = "5",
doi = "10.1016/j.jacc.2011.02.049",
language = "English",
volume = "58",
pages = "101--116",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier Inc.",
number = "2",
}